Genitope Corporation (Nasdaq:GTOP) today announced that it will be hosting a conference call on Thursday, August 17, at 8:30 a.m. (EDT) to discuss the previously provided Kaplan-Meier curve and additional related interim data from the Phase 3 clinical trial of MyVax(R) personalized immunotherapy to be provided in a report on Form 8-K to be filed later today by Genitope Corporation with the Securities and Exchange Commission.
